SOST and osteoporosis: The preliminary safety information for the humanized anti-sclerostin monoclonal antibody, romosozumab, stemmed mainly from the FRAME (the fracture study in postmenopausal women with osteoporosis) [2], ARCH [3], and BRIDGE [4] clinical trials.